Table 2. Changes of clinical parameters after ASA therapy.
HOCM patients (n = 10) | Pre-ASA | Post-ASA | P-value | ||
---|---|---|---|---|---|
Age (years) | 64.7±12.6 | - | |||
Male | 4 (40) | - | |||
ASA procedure | |||||
The amount of injected alcohol (ml) | 3.3±1.3 | - | |||
The number of treated septal branches | 2.0±0.7 | - | |||
Peak CPK (IU/L) | 1740.5±635.7 | - | |||
Peak CPK-MB (IU/L) | 257.1±122.0 | - | |||
NYHA functional class | 2.5±0.5 | 1.1±0.3 | <0.001 | ||
BNP (pg/ml) | 496.1±361.7 | 238.2±155.5 | 0.004 | ||
HSTnT (ng/ml) | 0.01±0.03 | 0.03±0.04 | 0.64 | ||
TTE | |||||
IVST (mm) | 15.6±4.3 | 13.1±2.7 | 0.072 | ||
LVPWT (mm) | 11.5±4.3 | 11.3±4.4 | 0.38 | ||
LAD (mm) | 46.4±7.5 | 40.2±7.8 | 0.004 | ||
E/A | 1.3±0.5 | 1.1±0.7 | 0.16 | ||
E/e' (sep) | 25.1±9.7 | 19.1±5.9 | 0.010 | ||
E/e' (lat) | 17.6±8.6 | 9.8±3.1 | 0.022 | ||
Intra-LVPG (mmHg) | 60.2±39.9 | 21.7±22.7 | <0.001 | ||
SAM | 5 (50) | 2 (20) | 0.17 | ||
Intra-LVPG by catheter measurement (mmHg) | 81.0±63.0 | 26.6±31.2 | 0.002 | ||
18F-FDG-PET/CT imaging | |||||
Summed uptake score | 26.9±14.5 | 15.6±16.1 | 0.022 | ||
Extent score | 8.1±3.9 | 6.0±3.5 | 0.26 | ||
Mean SUV | Entire LV | 2.5±1.1 | 1.7±0.8 | 0.077 | |
Anteroseptal | 2.3±1.2 | 1.7±0.6 | 0.14 | ||
Inferior | 2.5±1.1 | 1.6±0.8 | 0.062 | ||
Lateral | 2.6±1.3 | 1.6±0.9 | 0.053 | ||
Maximum SUV | Entire LV | 5.6±2.6 | 3.2±2.1 | 0.040 | |
Anteroseptal | 4.5±2.6 | 2.9±1.6 | 0.12 | ||
Inferior | 4.4±2.9 | 2.5±1.5 | 0.085 | ||
Lateral | 5.5±2.6 | 2.9±2.2 | 0.024 | ||
CMR imaging | |||||
LV mass index (g/cm2) | 102.3±43.9 | 101.8±51.4 | 0.47 | ||
LVEF (%) | 59.7±7.3 | 60.4±10.2 | 0.56 | ||
Presence of LGE | 5 (50) | 5 (50) | 0.67 | ||
LVOT jet | 10 (100) | 7 (70) | 0.10 | ||
MR jet | 7 (70) | 3 (30) | 0.086 |
Data are expressed as mean ± standard deviation or number of the patients (percentage). P-value compares pre- and post-ASA for continuous variables using paired Student's t-test and for categorical variables by using chi-square test.
HOCM: obstructive hypertrophic cardiomyopathy, ASA: alcohol septal ablation, CPK: creatine phosphokinase, CPK-MB: creatine phosphokinase MB isoenzyme, NYHA: New York Heart Association, BNP: brain natriuretic peptide, TTE: transthoracic echocardiography, IVST: interventricular septum thickening, LVPWT: left ventricular posterior wall thickening, LAD: left atrium dimension, E/A: peak early diastolic LV filling velocity/peak atrial filling velocity ratio, E/e’ (sep) and E/e’ (lat): the ratio between standard Doppler-derived transmitral early diastolic velocity (E) and pulsed Doppler-derived early diastolic velocity of the mitral annulus (e’) measured at the septal site and at the lateral site of the mitral annulus, intra-LVPG: intra-LV pressure gradient SAM: systolic anterior motion of the mitral valve, 18F-FDG-PET/CT: myocardial 18F-fluorodeoxyglucose positron emission tomography/computed tomography, SUV: standardized uptake value, CMR: cardiac magnetic resonance, LV mass index: left ventricular mass index, LVEF: left ventricular ejection fraction, LGE: late gadolinium enhancement, LVOT: left ventricular outflow tract, MR: mitral regurgitation.